Payment overview · 2025
General Payments
$187.71
7 reported records · 7 companies
Healthcare provider profile · identity verified
Muhammad A Gul, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EAST LONGMEADOW, MA · NPI 1144438193
Verified facts
What the public records show
CMS Open Payments records show Muhammad A Gul, MD received $187.71 in general payments during 2025 across 7 reported records.
Baxter Healthcare accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 285 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Baxter Healthcare | Unresolved — no canonical attribution shown | $41.62 | 22.2% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $32.13 | 17.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.60 | 16.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.80 | 15.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.48 | 11.4% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $17.68 | 9.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.40 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $187.71 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $41.62 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $32.13 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.60 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 285 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
285 | 62 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1326 | 346 |
| Amlodipine Besylate | Amlodipine Besylate | 1000 | 264 |
| Lisinopril | Lisinopril | 633 | 174 |
| Losartan Potassium | Losartan Potassium | 510 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 507 | 118 |
| Omeprazole | Omeprazole | 443 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 415 | 103 |
| Gabapentin | Gabapentin | 402 | 75 |
| Metformin Hcl | Metformin Hcl | 391 | 101 |
| Sertraline Hcl | Sertraline Hcl | 384 | 77 |
| Ezetimibe | Ezetimibe | 360 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 340 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 329 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 308 | 80 |
| Eliquis | Apixaban | 285 | 62 |
| Simvastatin | Simvastatin | 264 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 263 | 71 |
| Furosemide | Furosemide | 249 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 230 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 214 | 81 |
| Meloxicam | Meloxicam | 213 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 59 |
| Trazodone Hcl | Trazodone Hcl | 200 | 47 |
| Alendronate Sodium | Alendronate Sodium | 198 | 47 |
| Oxycodone Hcl | Oxycodone Hcl | 182 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 42 |
| Jardiance | Empagliflozin | 163 | 31 |
| Carvedilol | Carvedilol | 155 | 47 |
| Lorazepam | Lorazepam | 146 | 32 |
| Tramadol Hcl | Tramadol Hcl | 144 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 29 |
| Trulicity | Dulaglutide | 140 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 21 |
| Donepezil Hcl | Donepezil Hcl | 138 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 133 | 35 |
| Metformin Hcl Er | Metformin Hcl | 131 | 28 |
| Allopurinol | Allopurinol | 122 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 26 |
| Pregabalin | Pregabalin | 112 | 21 |
| Finasteride | Finasteride | 111 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 109 | 27 |
| Methadone Hcl | Methadone Hcl | 109 | suppressed |
| Alprazolam | Alprazolam | 103 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 19 |
| Farxiga | Dapagliflozin Propanediol | 99 | 25 |
| Mirtazapine | Mirtazapine | 99 | 24 |
| Montelukast Sodium | Montelukast Sodium | 99 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 95 | 20 |
| Prednisone | Prednisone | 95 | 57 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 19 |
| Famotidine | Famotidine | 91 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 30 |
| Atenolol | Atenolol | 87 | 22 |
| Ozempic | Semaglutide | 83 | 13 |
| Clonazepam | Clonazepam | 81 | 14 |
| Lovastatin | Lovastatin | 81 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 75 | 16 |
| Clonidine Hcl | Clonidine Hcl | 74 | 15 |
| Memantine Hcl | Memantine Hcl | 74 | 13 |
| Potassium Chloride | Potassium Chloride | 74 | 23 |
| Januvia | Sitagliptin Phosphate | 73 | 12 |
| Glipizide | Glipizide | 72 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 21 |
| Warfarin Sodium | Warfarin Sodium | 71 | 12 |
| Myrbetriq | Mirabegron | 70 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 69 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 15 |
| Chlorthalidone | Chlorthalidone | 65 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 16 |
| Synthroid | Levothyroxine Sodium | 65 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | suppressed |
| Azithromycin | Azithromycin | 61 | 45 |
| Memantine Hcl Er | Memantine Hcl | 61 | 12 |
| Meclizine Hcl | Meclizine Hcl | 58 | 20 |
| Hydrocortisone | Hydrocortisone | 56 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 13 |
| Terazosin Hcl | Terazosin Hcl | 54 | 11 |
| Topiramate | Topiramate | 54 | 15 |
| Baclofen | Baclofen | 53 | 12 |
| Clotrimazole | Clotrimazole | 52 | 18 |
| Glimepiride | Glimepiride | 52 | 12 |
| Sucralfate | Sucralfate | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 11 |
| Doxepin Hcl | Doxepin Hcl | 47 | suppressed |
| Irbesartan | Irbesartan | 46 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Valsartan | Valsartan | 44 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Ketoconazole | Ketoconazole | 40 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | 11 |
| Naltrexone Hcl | Naltrexone Hcl | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | 11 |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 11 |
| Tradjenta | Linagliptin | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Gemtesa | Vibegron | 34 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 29 |
| Fentanyl | Fentanyl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 17 |
| Linzess | Linaclotide | 30 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 11 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 24 | suppressed |
| Buprenorphine | Buprenorphine | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Digoxin | Digoxin | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 18 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Belbuca | Buprenorphine Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Rinvoq | Upadacitinib | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $187.71 · 7 records | Baxter Healthcare | ELIQUIS, Hillrom - Carnation Ambulatory Monitor, NURTEC ODT, Ohtuvayre, Ozempic, Rybelsus, SUBLOCADE, VIVITROL, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error